Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Cash (2021 - 2025)

Historic Change in Cash for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $17.6 million.

  • Prime Medicine's Change in Cash fell 7205.09% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 16295.18%. This contributed to the annual value of $141.5 million for FY2024, which is 19686.54% up from last year.
  • Per Prime Medicine's latest filing, its Change in Cash stood at $17.6 million for Q3 2025, which was down 7205.09% from -$38.4 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Change in Cash peaked at $139.7 million during Q4 2022, and registered a low of -$90.6 million during Q1 2025.
  • Its 5-year average for Change in Cash is -$7.2 million, with a median of -$17.0 million in 2022.
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 669145.82% in 2022, then crashed by 27228.07% in 2025.
  • Prime Medicine's Change in Cash (Quarter) stood at -$2.1 million in 2021, then surged by 6691.46% to $139.7 million in 2022, then plummeted by 101.71% to -$2.4 million in 2023, then soared by 2804.36% to $64.5 million in 2024, then plummeted by 72.73% to $17.6 million in 2025.
  • Its last three reported values are $17.6 million in Q3 2025, -$38.4 million for Q2 2025, and -$90.6 million during Q1 2025.